Mapping research trends of retinal vein occlusion from 2009 to 2018: a bibliometric analysis.

OBJECTIVES: To map publication trends and explore research hotspots of retinal vein occlusion (RVO) study. METHODS: Based on Web of Science Core Collection (WoSCC), a bibliometric analysis was carried out. The knowledge map was constructed by VOSviewer v.1.6.10 to visualize the annual publication number, the distribution of countries, international collaborations, author productivity, source journals, cited reference and keywords in this field. RESULTS: A total of 2,135 peer-reviewed papers were retrieved on RVO from 2009 to 2018. The United States ranks highest among countries with the most publications and the most active institution was Kyoto University. Noma H contributed the most publications in this field. Retina-The Journal of Retinal and Vitreous Disease was the most prolific journal in RVO research. The top cited references mainly presented anti-VEGF medications on the management of RVO. The keywords formed six clusters: (1) Risk factors and pathogenesis of RVO; (2) Metabolismof RVO; (3) Therapeutic use of corticosteroids on RVO; (4) Diagnostic methodsof RVO; (5) Management of macular edema secondary to RVO (6) Anti-VEGFtreatment of RVO. CONCLUSIONS: The six major research hotspots could provide an insight into RVO research and valuable information for researchers to identify potential collaborators and partner institutions.

Trends in Research Related to Keratoconus From 2009 to 2018: A Bibliometric and Knowledge Mapping Analysis.

PURPOSE: To map the publication trends in and explore hotspots of keratoconus research. METHODS: A bibliometric analysis based on the Web of Science Core Collection was conducted to investigate the publication trends in research related to keratoconus. The records extracted were analyzed, and a knowledge map was constructed using VOSviewer v.1.6.10 to visualize the annual publication number, distribution of countries, international collaborations, author productivity, source journals, intellectual base, and research hotspots in the field of keratoconus. RESULTS: In total, 3194 peer-reviewed publications on keratoconus published between 2009 and 2018 were retrieved, and the annual research output increased with time. The United States ranked the highest among the countries with the most publications, and Tehran University of Medical Sciences was the most active institution. JL Alio contributed to the most number of publications on keratoconus, and Cornea was the most prolific journal publishing keratoconus research. The top cited references mainly focused on corneal collagen cross-linking. The keywords formed 6 clusters: 1) pathogenesis of keratoconus, 2) corneal collagen cross-linking, 3) management for early-stage keratoconus, 4) corneal parameter measurement, 5) surgical treatment of keratoconus, and 6) corneal biomechanics-related research. CONCLUSIONS: On the basis of the data extracted from the Web of Science Core Collection, the quantity and quality of publications on keratoconus were assessed using bibliometric techniques. The cited references and research hotspots could provide insights into keratoconus research as well as valuable information to cornea specialists for performing research in this field and discovering potential collaborators.

Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression.

Patients with advanced epithelial ovarian cancer often experience disease recurrence after standard therapies, a critical factor in determining their five-year survival rate. Recent reports indicated that long-term or short-term survival is associated with varied gene expression of cancer cells. Thus, identification of novel prognostic biomarkers should be considered. Since the mouse genome is similar to the human genome, we explored potential prognostic biomarkers using two groups of mouse ovarian cancer cell lines (group 1: IG-10, IG-10pw, and IG-10pw/agar; group 2: IG-10 clones 2, 3, and 11) which display highly and moderately aggressive phenotypes in vivo. Mice injected with these cell lines have different survival time and rates, capacities of tumor, and ascites formations, reflecting different prognostic potentials. Using an Affymetrix Mouse Genome 430 2.0 Array, a total of 181 genes were differentially expressed (P < 0.01) by at least twofold between two groups of the cell lines. Of the 181 genes, 109 and 72 genes were overexpressed in highly and moderately aggressive cell lines, respectively. Analysis of the 109 and 72 genes using Ingenuity Pathway Analysis (IPA) tool revealed two cancer-related gene networks. One was associated with the highly aggressive cell lines and affiliated with MYC gene, and another was associated with the moderately aggressive cell lines and affiliated with the androgen receptor (AR). Finally, the gene enrichment analysis indicated that the overexpressed 89 genes (out of 109 genes) in highly aggressive cell lines had a function annotation in the David database. The cancer-relevant significant gene ontology (GO) terms included Cell cycle, DNA metabolic process, and Programmed cell death. None of the genes from a set of the 72 genes overexpressed in the moderately aggressive cell lines had a function annotation in the David database. Our results suggested that the overexpressed MYC and 109 gene set represented highly aggressive ovarian cancer potential biomarkers while overexpressed AR and 72 gene set represented moderately aggressive ovarian cancer potential biomarkers. Based on our knowledge, the current study is first time to report the potential biomarkers relevant to different aggressive ovarian cancer. These potential biomarkers provide important information for investigating human ovarian cancer prognosis.

Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase.

The association of B7-1/CD28 between antigen presenting cells (APCs) and T-cells provides a second signal to proliferate and activate T-cell immunity at the induction phase. Many reports indicate that tumor cells transfected with B7-1 induced augmented antitumor immunity at the induction phase by mimicking APC function; however, the function of B7-1 on antitumor immunity at the effector phase is unknown. Here, we report direct evidence of enhanced T-cell antitumor immunity at the effector phase by the B7-1 molecule. Our experiments in vivo and in vitro indicated that reactivity of antigen-specific monoclonal and polyclonal T-cell effectors against a Lass5 epitope presented by RMA-S cells is increased when the cells expressed B7-1. Use of either anti-B7-1 or anti-CD28 antibodies to block the B7-1/CD28 association reduced reactivity of the T effectors against B7-1 positive RMA-S cells. Transfection of Lass5 cDNA into or pulse of Lass5 peptide onto B7-1 positive RMA-S cells overcomes the requirement of the B7-1/CD28 signal for T effector response. To our knowledge, the data offers, for the first time, strong evidence that supports the requirement of B7-1/CD28 secondary signal at the effector phase of antitumor T-cell immunity being dependent on the density of an antigenic peptide.